Is Mankind Pharma overvalued or undervalued?

As of 2 July 2025, Mankind Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued. Key ratios include a PE Ratio of 49.48, an EV to EBITDA of 31.08, and a Price to Book Value of 9.32, all of which are considerably higher than industry norms.
In comparison to peers, Mankind Pharma's PE Ratio is notably higher than Sun Pharma's 35.25 and Cipla's 22.92, further emphasizing its overvaluation. Additionally, its EV to EBITDA ratio of 31.08 is also above the industry average, with competitors like Dr. Reddy's Labs and Aurobindo Pharma showing more attractive valuations at 12.39 and 10.35, respectively. Despite a recent 1-week stock return of 3.2%, Mankind Pharma has underperformed the Sensex year-to-date, highlighting concerns about its high valuation amidst a broader market context.